Proactive Investors - Run By Investors For Investors

Zynerba Pharmaceuticals adds pharma exec to its board

Pamela Stephenson brings expertise in commercial planning to the developer of transdermal cannabinoid therapies
board room table
The Devon, Pennsylvania company develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said Wednesday that it has appointed Pamela Stephenson to its board of directors.

Stephenson is currently vice president of Global Market Access and Value at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), where she has served since 2008. Prior to that, she spent 10 years at Pfizer Inc (NYSE:PFE) in various capacities.

“Zynerba is in an important phase of its journey as it begins its preparations for a potential launch of the first product ever indicated for use in children and adolescents with Fragile X Syndrome,” said Stephenson in a statement. “I am excited to join Zynerba’s board of directors at this time, and look forward to contributing to the company’s future successes.”

The Devon, Pennsylvania, company develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X Syndrome – a genetic cause of intellectual disability -- and Autism Spectrum Disorder.

“Pamela brings with her a wealth of expertise in commercial planning, market development, product launch and market access,” said Zynerba CEO Armando Anido. “This experience will be essential as we develop the market for ZYN002 in Fragile X Syndrome and await data from our ongoing pivotal CONNECT-FX study.”

Zynerba shares closed at $5.03 Tuesday.

Contact Paul Curcio at [email protected]

Follow him on Twitter @GoCurcioGo

View full ZYNE profile View Profile

Zynerba Pharmaceuticals Timeline

Related Articles

Scientists in a lab
January 30 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use